CClinicalTrials.gg
RecruitingNCT05315505Rehab2lifeUpdated Aug 24, 2023

Effectiveness of a Home-based Pulmonary Rehabilitation Program in COPD Patients

An interventional study of Maintenance programme and Usual Care in Chronic Obstructive Pulmonary Disease and Pulmonary Rehabilitation, sponsored by Unidade Local de Saúde de Matosinhos, EPE. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-24.

Sponsored by Unidade Local de Saúde de Matosinhos, EPE · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to develop and test the effectiveness of a new home-based pulmonary rehabilitation program comprising two distinct phases, the first in which an 8-week respiratory rehabilitation program is carried out the second in which a maintenance pulmonary rehabilitation program is carried out.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Pulmonary Rehabilitation

Keywords

  • COPD
  • Pulmonary rehabilitation
  • Maintenance pulmonary rehabilitation
03

In context

Lung Diseases, Obstructive

2,592 studies on the registry are indexed under Lung Diseases, Obstructive; 198 are open to participants now.

This study's planned enrollment of 160 is above the median of 66 across 1,837 interventional studies indexed under Lung Diseases, Obstructive.

Browse Lung Diseases, Obstructive studies →

Lead sponsor

Unidade Local de Saúde de Matosinhos, EPE is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • COPD diagnose with B or E characterization according to GOLD criteria;
  • Residence in the area covered by the institution where the study is carried out

Exclusion criteria

Exclusion Criteria:

  • Frequency of a PR programme in the previous six months
  • COPD exacerbation for less than one week;
  • Presence of unstable comorbidities (List of predetermined diagnoses that constitute absolute exclusion criteria);
  • Presence of comorbidities that constitute relative exclusion criteria through a medical evaluation.
  • Score of the Clinical Frailty Scale 2.0 above six or above five in case of not having a responsible caregiver and living alone
  • SpO2 below 85% in the 6-minute walk test
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Maintenance

    Participants will undergo an initial home-based pulmonary rehabilitation program for eight weeks. At the end of the eight weeks, the participants will be randomly assigned into two groups, one receiving the maintenance pulmonary rehabilitation program and the other receiving the usual care. The maintenance arm will receive home visits for supervised physical exercise and progressively alternated with phone calls to motivation and feedback

    Other: Maintenance programme

  • Active comparator
    control

    Participants will undergo an initial home-based pulmonary rehabilitation program for eight weeks. At the end of the eight weeks, the participants will be randomly assigned into two groups, one receiving the maintenance pulmonary rehabilitation program and the other receiving the usual care. The control group will have access to the usual follow.

    Other: Usual Care

Interventions

  • OtherMaintenance programme

    Continuous educational support, exercise training, behaviour change intervention, and self-management. Maintenance home-based pulmonary rehabilitation programme for ten months with alternate supervision

    Also known as: Physical exercise, Behaviour change, Self-management

  • OtherUsual Care

    No maintenance programme, and the patient has the usual follow-up and medical appointments

06

What researchers measure

Primary outcomes

  1. Distance in meters covered over a time of 6 minutes 0

    Distance in meters covered over a time of 6 minutes 0 measured with the 6 minute walking test (6MWT) - The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance in meters covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

    Time frame: Baseline

  2. Distance in meters covered over a time of 6 minutes 1

    Distance in meters covered over a time of 6 minutes 1 measured with the 6 minute walking test (6MWT) - The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance in meters covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

    Time frame: 8 weeks

  3. Distance in meters covered over a time of 6 minutes 2

    Distance in meters covered over a time of 6 minutes 2 measured with the 6 minute walking test (6MWT) - The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance in meters covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

    Time frame: 7 months

  4. Distance in meters covered over a time of 6 minutes 3

    Distance in meters covered over a time of 6 minutes 3 measured with the 6 minute walking test (6MWT) - The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance in meters covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

    Time frame: 12 months

Secondary outcomes

  1. Dyspnoea 0

    modified Medical Research Council dyspnoea scale (mMRC) - Range from 1 to 5, The higher the score, the worst the dyspnoea

    Time frame: Baseline

  2. Dyspnoea 1

    modified Medical Research Council dyspnoea scale (mMRC) - Range from 1 to 5, The higher the score, the worst the dyspnoea

    Time frame: 8 weeks

  3. Dyspnoea 2

    modified Medical Research Council dyspnoea scale (mMRC) - Range from 1 to 5, The higher the score, the worst the dyspnoea

    Time frame: 7 months

  4. Dyspnoea 3

    modified Medical Research Council dyspnoea scale (mMRC) - Range from 1 to 5, The higher the score, the worst the dyspnoea

    Time frame: 12 months

  5. Health-Related Quality of Life 0

    European quality of life-5 dimensions (EQ5D)

    Time frame: Baseline

  6. Health-Related Quality of Life 1

    European quality of life-5 dimensions (EQ5D)

    Time frame: 8 weeks

  7. Health-Related Quality of Life 2

    European quality of life-5 dimensions (EQ5D)

    Time frame: 7 months

  8. Health-Related Quality of Life 3

    European quality of life-5 dimensions (EQ5D)

    Time frame: 12 months

  9. Number of emergency department visits due to COPD exacerbation 0

    Number of exacerbations (accessing to emergency department)

    Time frame: Baseline

  10. Number of emergency department visits due to COPD exacerbation 1

    Number of exacerbations (accessing to emergency department)

    Time frame: 8 weeks

  11. Number of emergency department visits due to COPD exacerbation 2

    Number of exacerbations (accessing to emergency department)

    Time frame: 7 months

  12. Number of emergency department visits due to COPD exacerbation 3

    Number of exacerbations (accessing to emergency department)

    Time frame: 12 months

  13. COPD symptom control 0

    COPD Assessment Test - Range from 0 to 40. The higher the score, the worst the clinical control

    Time frame: Baseline

  14. COPD symptom control 1

    COPD Assessment Test - Range from 0 to 40. The higher the score, the worst the clinical control

    Time frame: 8 weeks

  15. COPD symptom control 2

    COPD Assessment Test - Range from 0 to 40. The higher the score, the worst the clinical control

    Time frame: 7 months

  16. COPD symptom control 3

    COPD Assessment Test - Range from 0 to 40. The higher the score, the worst the clinical control

    Time frame: 12 months

  17. Anxiety and Depression 0

    Hospital Anxiety and Depression Scale (HADS) - HADS is a fourteen-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score \>8 denotes anxiety or depression. HADS scoring was done before and after low-vision consultation to see whether there was a change in the scoring

    Time frame: Baseline

  18. Anxiety and Depression 1

    Hospital Anxiety and Depression Scale (HADS) - HADS is a fourteen-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score \>8 denotes anxiety or depression. HADS scoring was done before and after low-vision consultation to see whether there was a change in the scoring

    Time frame: 8 weeks

  19. Anxiety and Depression 2

    Hospital Anxiety and Depression Scale (HADS) - HADS is a fourteen-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score \>8 denotes anxiety or depression. HADS scoring was done before and after low-vision consultation to see whether there was a change in the scoring

    Time frame: 7 months

  20. Anxiety and Depression 3

    Hospital Anxiety and Depression Scale (HADS) - HADS is a fourteen-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score \>8 denotes anxiety or depression. HADS scoring was done before and after low-vision consultation to see whether there was a change in the scoring

    Time frame: 12 months

  21. Physical activity 0

    Counting steps per day with the pedometer Yamax EX510

    Time frame: Baseline

  22. Physical activity 1

    Counting steps per day with the pedometer Yamax EX510

    Time frame: 8 weeks

  23. Physical activity 2

    Counting steps per day with the pedometer Yamax EX510

    Time frame: 7 months

  24. Physical activity 3

    Counting steps per day with the pedometer Yamax EX510

    Time frame: 12 months

  25. Functional capacity 0

    Number of times per minute an individual is able to stand up and sit down on a chair standardised for height

    Time frame: Baseline

  26. Functional capacity 1

    Number of times per minute an individual is able to stand up and sit down on a chair standardised for height

    Time frame: 8 weeks

  27. Functional capacity 2

    Number of times per minute an individual is able to stand up and sit down on a chair standardised for height

    Time frame: 7 months

  28. Functional capacity 3

    Number of times per minute an individual is able to stand up and sit down on a chair standardised for height

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05315505
Lead sponsor
Unidade Local de Saúde de Matosinhos, EPE
Responsible party
Liliana Silva (RN, Unidade Local de Saúde de Matosinhos, EPE) — Principal investigator
First posted
Apr 7, 2022
Start date
May 9, 2022
Primary completion
Dec 2023 (estimated)
Completion
Apr 2024 (estimated)
Last update
Aug 24, 2023

Study contacts

Liliana Silva, MSc
Contact
enf.lilianasilva@gmail.com
+351917556931
Miguel Padilha, PhD
Contact
miguelpadilha@esenf.pt
Liliana Silva, MSc
principal investigator · Matosinhos Local Health Unit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion